<DOC>
	<DOCNO>NCT01986881</DOCNO>
	<brief_summary>A study cardiovascular outcome follow treatment ertugliflozin participant type 2 diabetes mellitus ( T2DM ) establish vascular disease . The main objective study ass cardiovascular safety ertugliflozin . This trial include pre-defined glycemic sub-study participant receive background insulin without metformin , pre-defined glycemic sub-study participant receive background sulfonylurea monotherapy , pre-defined sub-study participant receive background metformin sulfonylurea ( fully-enrolled ) .</brief_summary>
	<brief_title>Cardiovascular Outcomes Following Ertugliflozin Treatment Type 2 Diabetes Mellitus Participants With Vascular Disease , The VERTIS CV Study ( MK-8835-004 )</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Vascular Diseases</mesh_term>
	<criteria>Diagnosis T2DM accordance American Diabetes Association ( ADA ) guideline Hemoglobin A1c ( HbA1c ) start study participation 7.010.5 % ( 5391 mmol/mol ) On stable allowable antihyperglycemic agent ( AHA ) background AHA least 8 week prior study participation Body Mass Index ( BMI ) &gt; = 18.0 kg/m^2 Evidence history atherosclerosis involve coronary , cerebral peripheral vascular system There adequate documentation objective evidence participant establish vascular disease investigational site 's medical record , copy record institution , letter refer physician specifically state diagnosis date recent occurrence qualify event ( ) procedure ( ) . Male , female reproductive potential , female reproductive potential agree abstinent heterosexual activity agree use partner use 2 acceptable method contraception Previous randomization trial ertugliflozin Experiencing cardiovascular event ( myocardial infarction stroke ) undergo coronary angioplasty peripheral intervention procedure Screening Visit randomization Undergoing cardiovascular surgery ( valvular surgery ) within 3 month study participation Planned revascularization peripheral intervention procedure cardiovascular surgery New York Heart Association ( NYHA ) IV heart failure study participation History type 1 diabetes mellitus history ketoacidosis</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>